London-based Cryogenx has raised €1.9 million as a part of Seed funding spherical to speed up the event of its transportable cooling expertise to fight warmth strokes.
The UK Innovation & Science Seed Fund (UKI2S), managed by Future Planet Capital, has invested €495k in Cryogenx as a part of the funding spherical.
Founder and CEO of Cryogenx, Matt Anderson, added: “Heatstroke isn’t simply an remoted danger; it’s a rising international menace – and current options merely aren’t sensible sufficient to fulfill the problem. We’ve designed CGX1 as a defibrillator for heatstroke, offering frontline responders and navy personnel the flexibility to deal with heat-related sickness successfully, wherever it strikes.
“The backing from UKI2S is pivotal – it not solely validates our mission however offers us the sources to speed up regulatory clearance, scale manufacturing, and get this lifesaving expertise into the arms of those that want it most.“
Based in 2020, Cryogenx develops transportable on-demand cooling units designed to quickly deal with heatstroke and heat-related sicknesses in-the-field. Their flagship product, CGX1, eliminates the necessity for cold-chain logistics and may be deployed in distant, industrial, navy, and emergency response settings.
The corporate is concentrating on international markets throughout defence, business, and local weather adaptation sectors.
The CGX1, is designed to ship speedy, life-saving remedy for heatstroke and heat-related illness- all with out the necessity for ice, refrigeration, or complicated cold-chain logistics. Described as a “defibrillator for warmth”, the light-weight machine may be deployed in minutes, making it a possible game-changer for navy, industrial, and emergency response functions the place excessive temperatures put lives and operations in danger.
“That is precisely the type of innovation we goal in our defence and safety investments,” mentioned Alex Leigh, Funding Director at UKI2S, managed by Future Planet Capital. “Cryogenx is addressing a essential, international problem with an answer that has the potential to remodel how we stop and handle warmth accidents throughout sectors. We’re proud to help them as they scale their affect and set a brand new benchmark for operational security and resilience.”
Cryogenx is concentrated on dual-use functions, with sturdy relevance for defence prospects just like the UK Ministry of Defence (MOD) and the US Division of Protection (DoD), the place Cryogenx says exertional warmth sickness is a persistent and dear challenge. The corporate can be eyeing speedy enlargement into civilian sectors, together with power, development, mining, emergency providers, and sports activities.
The funding shall be used to drive FDA clearance, scale up manufacturing, and develop worldwide gross sales. Cryogenx can be growing lighter, modular variations of its expertise and planning a subscription-based mannequin to construct long-term income.
By 2030, 700 million individuals are projected to be uncovered to excessive warmth, with the ensuing productiveness losses anticipated to prime €2 trillion yearly. Core physique temperatures exceeding 39°C may be deadly, and even sub-lethal warmth stress sharply reduces bodily and cognitive efficiency – in line with information offered by Cryogenx.
4 environmental components – temperature, humidity, radiant warmth, and wind velocity – mix to push staff past secure limits, in line with analysis from the Nationwide Institute for Occupational Security and Well being (NIOSH). As soon as physique temperatures rise above 38°C, warmth exhaustion units in; at 40.6°C, the chance of organ failure and loss of life from heatstroke will increase dramatically.
Cryogenx’s innovation appears to deal with this head-on, offering a scalable, transportable answer at a time when climate-driven warmth stress is rising as some of the pressing international well being and financial challenges.
